Back to Search Start Over

Broadly neutralizing antibodies potently inhibit cell-to-cell transmission of semen leukocyte-derived SHIV162P3

Authors :
Karunasinee, Suphaphiphat
Monica, Tolazzi
Stéphane, Hua
Delphine, Desjardins
Valerie, Lorin
Nathalie, Dereuddre-Bosquet
Hugo, Mouquet
Gabriella, Scarlatti
Roger Le, Grand
Mariangela, Cavarelli
CCSD, Accord Elsevier
Infrastructures - Infrastructure nationale pour la modélisation des maladies infectieuses humaines - - IDMIT2011 - ANR-11-INBS-0008 - INBS - VALID
Equipements d'excellence - Plateforme de phénotypage en Mass cytométrie pour l'analyse multiparamétrique de biomarqueurs complexes de l'efficacité de nouvelles stratégies thérapeutiques ou vaccinales - - FlowCyTech2010 - ANR-10-EQPX-0002 - EQPX - VALID
European AIDS Vaccine Initiative 2020 - EAVI2020 - - H20202015-11-01 - 2020-10-31 - 681137 - VALID
Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB)
Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay
IRCCS San Raffaele Scientific Institute [Milan, Italie]
Immunologie humorale - Humoral Immunology
Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)
This work was funded by the French Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) and the European AIDS Vaccine Initiative 2020 (EAVI2020, grant agreement n° 681137) of the H2020 European program. MC was a beneficiary of a Marie Curie Individual fellowship (grant agreement n° 658277 for the project DCmucoHIV). KS was supported by fellowships from the ANRS (n° 2016–313) and the Franco-Thai Program (n° 849249B). This work was also supported by the 'Programme Investissements d'Avenir' (PIA) managed by the ANR under reference ANR-11-INBS-0008, funding the Infectious Disease Models and Innovative Therapies (IDMIT, Fontenay-aux-Roses, France) infrastructure, and ANR-10-EQPX-02–01, funding the FlowCyTech facility (IDMIT, Fontenay-aux-Roses, France). It also benefits of the support of 'Fond de Dotation Pierre Bergé' (SIDACTION, France).
ANR-11-INBS-0008,IDMIT,Infrastructure nationale pour la modélisation des maladies infectieuses humaines(2011)
ANR-10-EQPX-0002,FlowCyTech,Plateforme de phénotypage en Mass cytométrie pour l'analyse multiparamétrique de biomarqueurs complexes de l'efficacité de nouvelles stratégies thérapeutiques ou vaccinales(2010)
European Project: 681137,H2020,H2020-PHC-2015-single-stage_RTD,EAVI2020(2015)
Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)
Source :
EBioMedicine, Vol 57, Iss, Pp 102842-(2020), EBioMedicine, EBioMedicine, 2020, 57, pp.102842. ⟨10.1016/j.ebiom.2020.102842⟩, EBioMedicine, Elsevier, 2020, 57, pp.102842-. ⟨10.1016/j.ebiom.2020.102842⟩
Publication Year :
2020
Publisher :
Elsevier, 2020.

Abstract

Background HIV-1 sexual transmission occurs mostly through infected semen, which contains both free virions and infected leukocytes. Transmission initiated by infected cells has been shown by several in vitro and in vivo studies and a reduced capacity of broadly neutralizing antibodies (bNAbs) to inhibit cell-to-cell transmission has also been reported. However, due to limitations of available experimental models, there is yet no clarity to which extend bNAbs can prevent transmission mediated by semen leukocytes. Methods We developed a novel in vitro assay to measure cell-cell transmission that makes use of splenocytes or CD45+ semen leukocytes collected from acutely SHIV162P3-infected cynomolgus macaques. A panel of 11 bNAbs was used either alone or in combination to assess their inhibitory potential against both cell-free and cell-cell infection. Findings Splenocytes and semen leucocytes displayed a similar proportion of CD4+T-cell subsets. Either cell type transferred infection in vitro to target TZM-bl cells and PBMCs. Moreover, infection of macaques was achieved following intravaginal challenge with splenocytes. The anti-N-glycans/V3 loop bNAb 10–1074 was highly efficient against cell-associated transmission mediated by infected spleen cells and its potency was maintained when transmission was mediated by CD45+ semen leukocytes. Interpretation These results support the use of bNAbs in preventative or therapeutic studies aiming to block transmission events mediated not only by free viral particles but also by infected cells. Our experimental system could be used to predict in vivo efficacy of bNAbs. Funding This work was funded by the 10.13039/501100003323ANRS and the European Commission.

Details

Language :
English
ISSN :
23523964
Volume :
57
Database :
OpenAIRE
Journal :
EBioMedicine
Accession number :
edsair.pmid.dedup....637b3ca6f873df2180bbdd5a95d2ce3d
Full Text :
https://doi.org/10.1016/j.ebiom.2020.102842⟩